Pan, S. et al. High throughput proteome screening for biomarker detection. Mol. Cell. Proteomics 4, 182-190

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Molecular & Cellular Proteomics (Impact Factor: 6.56). 03/2005; 4(2):182-90. DOI: 10.1074/mcp.M400161-MCP200
Source: PubMed


Mass spectrometry-based quantitative proteomics has become an important component of biological and clinical research. Current methods, while highly developed and powerful, are falling short of their goal of routinely analyzing whole proteomes mainly because the wealth of proteomic information accumulated from prior studies is not used for the planning or interpretation of present experiments. The consequence of this situation is that in every proteomic experiment the proteome is rediscovered. In this report we describe an approach for quantitative proteomics that builds on the extensive prior knowledge of proteomes and a platform for the implementation of the method. The method is based on the selection and chemical synthesis of isotopically labeled reference peptides that uniquely identify a particular protein and the addition of a panel of such peptides to the sample mixture consisting of tryptic peptides from the proteome in question. The platform consists of a peptide separation module for the generation of ordered peptide arrays from the combined peptide sample on the sample plate of a MALDI mass spectrometer, a high throughput MALDI-TOF/TOF mass spectrometer, and a suite of software tools for the selective analysis of the targeted peptides and the interpretation of the results. Applying the method to the analysis of the human blood serum proteome we demonstrate the feasibility of using mass spectrometry-based proteomics as a high throughput screening technology for the detection and quantification of targeted proteins in a complex system.

Download full-text


Available from: Hui Zhang
  • Source
    • "The relative quantification needs efficient labeling of the detected peptides or proteins and also relies on the accuracy of the mass measurement and the chromatographic reproducibility . In contrast to the relative quantification strategies just described, the absolute quantification of proteins is attractive in many studies, such as discovery of new biomarkers in vast clinical samples (Pan et al., 2005). When the absolute quantification of proteins is known in different samples, then their relative ratios can be calculated readily. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the post-genomics era, proteomics has become a central branch in life sciences. An understanding of biological functions will not only rely on protein identification, but also on protein quantification in a living organism. Most of the existing methods for quantitative proteomics are based on isotope labeling combined with molecular mass spectrometry. Recently, a remarkable progress that utilizes inductively coupled plasma-mass spectrometry (ICP-MS) as an attractive complement to electrospray MS and MALDI MS for protein quantification, especially for absolute quantification, has been achieved. This review will selectively discuss the recent advances of ICP-MS-based technique, which will be expected to further mature and to become one of the key methods in quantitative proteomics.
    Full-text · Article · Mar 2010 · Mass Spectrometry Reviews
    • "However, analysis of these fluids pose limitations to studying disease-associated proteins because of the wide dynamic range of proteins and abundance of common proteins in complex biological samples. These limitations, in part, explain the inability to discover low abundance serum proteins [35] [36] [37]. A more focused approach would be to deconstruct CICs as the key contributors to pathology. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Juvenile idiopathic arthritis reflects a group of clinically heterogeneous arthritides hallmarked by elevated concentrations of circulating immune complexes. In this study, the circulating immune complex proteome was examined to elucidate disease-associated proteins that are overexpressed in patients with an aggressive, and at times destructive, disease phenotype. To solve this proteome, circulating immune complexes were isolated from the sera of patients with chronic, erosive or early-onset, aggressive disease and from patients in medical remission or healthy controls subsequent to protein separation by 2-DE. Thirty-seven protein spots were overexpressed in the circulating immune complexes of the aggressive disease groups as compared to controls, 28 of which have been confidently identified to date. Proteolytic fragments of glyceraldehyde-3-phosphate dehydrogenase, serotransferrin, and α-1-antitrypsin have been identified among others. In total, these 28 putative disease-associated proteins most definitely contribute to immune complex formation and likely have a significant role in disease etiology and pathogenesis. Moreover, these proteins represent markers of aggressive disease, which could aid in diagnosis and management strategies, and potential therapeutic targets to prevent or control disease outcome. This is the first in-depth analysis of the circulating immune complex proteome in juvenile idiopathic arthritis.
    No preview · Article · Jul 2009 · PROTEOMICS - CLINICAL APPLICATIONS
  • Source
    • "The major difficulty associated with these approaches centers on the availability of specific antibodies against novel proteins identified by proteomics and the difficulty to detect changes of low abundant proteins/peptides by these methods. To circumvent this problem, several groups of investigators are actively involved in MS-based targeted quantitative proteomics (Aebersold, 2003; Anderson, 2005; Gerber et al., 2003; Pan et al., 2005). This technology uses isotope dilution followed by MS analysis, in which test-samples are supplemented (spiked) with isotope-labeled synthetic peptides, which serve as the signature markers for the identification and quantification of native peptides (target) within each sample. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Biomarkers for neurodegenerative disorders are essential to facilitate disease diagnosis, ideally at early stages, monitor disease progression, and assess response to existing and future treatments. Application of proteomics to the human brain, cerebrospinal fluid and plasma has greatly hastened the unbiased and high-throughput searches for novel biomarkers. There are many steps critical to biomarker discovery, whether for neurodegenerative or other diseases, including sample preparation, protein/peptide separation and identification, as well as independent confirmation and validation. In this review we have summarized current proteomics technologies involved in discovery of biomarkers for neurodegenerative diseases, practical considerations and limitations of several major aspects, as well as the current status of candidate biomarkers revealed by proteomics for Alzheimer and Parkinson diseases.
    Full-text · Article · Oct 2008 · Neurobiology of Disease
Show more